UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?

Bone marrow transplantation (Basingstoke), 2006-07, Vol.38 (2), p.95-100

2006

Volltextzugriff (PDF)

249 CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY

Leukemia research, 2015-04, Vol.39, p.S124-S124

2015

Volltextzugriff (PDF)

Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer

The New England journal of medicine, 2009-05, Vol.360 (20), p.2055-2065

2009

Volltextzugriff (PDF)

Azacitidine in Lower‐Risk Myelodysplastic Syndromes: A Meta‐Analysis of Data from Prospective Studies

The oncologist (Dayton, Ohio), 2018-02, Vol.23 (2), p.159-170

2018

Volltextzugriff (PDF)

P121 Patients with hematologic disorders receiving azacitidine who are enrolled in AVIDA, a longitudinal patient registry, achieve transfusion independence

Leukemia research, 2009-05, Vol.33, p.S129-S130

2009

Volltextzugriff (PDF)

Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation

Bone marrow transplantation (Basingstoke), 2006-03, Vol.37 (6), p.553-557

2006

Volltextzugriff (PDF)

Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?

Bone marrow transplantation (Basingstoke), 2006-09, Vol.38 (5), p.397-397

2006

Volltextzugriff (PDF)

Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation

Bone marrow transplantation (Basingstoke), 2006-09, Vol.38 (5), p.397-397

2006

Volltextzugriff (PDF)

A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer

Bone marrow transplantation (Basingstoke), 2001-04, Vol.27 (7), p.677-681

2001

Volltextzugriff (PDF)

High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer : a 10-year experience

Bone marrow transplantation (Basingstoke), 1998-01, Vol.21 (2), p.127-132

1998

Volltextzugriff (PDF)

Autologous and allogeneic transplantation for aggressive NHL

Cytotherapy (Oxford, England), 2002-05, Vol.4 (3), p.223-240

2002

Volltextzugriff (PDF)

A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma

Cancer, 1998-10, Vol.83 (8), p.1540-1545

1998

Volltextzugriff (PDF)

Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer

Cytotherapy (Oxford, England), 2000-03, Vol.2 (3), p.179-185

2000

Volltextzugriff (PDF)

Toward understanding toxicity over time (ToxT) in myeloma cooperative group trials: Feasibility of a novel longitudinal adverse event analysis in ECOG-ACRIN E1A06

Journal of clinical oncology, 2018, Vol.36 (15_suppl), p.6580-6580

2018

Volltextzugriff (PDF)

Patients with secondary myelodysplastic syndromes (MDS) who are enrolled in AVIDA, a longitudinal registry for patients receiving azacitidine (AZA)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.7094-7094

2009

Volltextzugriff (PDF)

Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma

Journal of clinical apheresis, 1999, Vol.14 (1), p.31-34

1999

Volltextzugriff (PDF)

Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer

Bone marrow transplantation (Basingstoke), 1995-06, Vol.15 (6), p.935-942

1995

Volltextzugriff (PDF)

Factors Affecting the Results of Allogeneic Hematopoietic Stem Cell Transplantation in Hematologic Malignancies

Blood, 2008-11, Vol.112 (11), p.4386-4386

2008

Volltextzugriff (PDF)

Response of pancreatic carcinoma to 5-fluorouracil and leucovorin

The American journal of medicine, 1992, Vol.92 (1), p.107-109

1992

Volltextzugriff (PDF)

Outcome of Submyeloablative Allogeneic HSCT for Hematologic Malignancies: Development of a Prognostic Model Based on Pre-Transplant Characteristics

Blood, 2005-11, Vol.106 (11), p.1145-1145

2005

Volltextzugriff (PDF)

Ideal (IBW) Rather Than Actual (ABW) Body Weight Should Be Used To Calculate Cell Dose in Allogeneic HSCT

Blood, 2005-11, Vol.106 (11), p.1765-1765

2005

Volltextzugriff (PDF)

Identifying Patients at Risk of Early Relapse after Submyeloablative Allogeneic HSCT

Blood, 2005-11, Vol.106 (11), p.5390-5390

2005

Volltextzugriff (PDF)

Graft CD3+ Cell Content Affects Acute GVHD after Submyeloablative Allogeneic HSCT

Blood, 2005-11, Vol.106 (11), p.3663-3663

2005

Volltextzugriff (PDF)

The Effect of the Platelet Content of Blood Stem Cell Grafts on GVHD

Blood, 2005-11, Vol.106 (11), p.1077-1077

2005

Volltextzugriff (PDF)

Is a Younger 10-Allele-Matched Unrelated Donor (MUD) Better Than an Older 6-Antigen-Matched Sibling Donor (MSD) for Allogeneic HSCT?

Blood, 2004-11, Vol.104 (11), p.2757-2757

2004

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(46)

Publikationsform

Sprache

Englisch
(49)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Humans
(18)
Female
(16)
Biological And Medical Sciences
(15)
Medical Sciences
(15)
Middle Aged
(14)
Oncology
(14)
Adult
(13)
Hematology
(13)
Male
(11)
Transplantation
(11)
Biophysics
(9)
Aged
(8)
Immunology
(8)
Pharmacology. Drug Treatments
(7)
Stem Cell Transplantation
(7)
Antineoplastic Agents
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Chemotherapy
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?

249 CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY

Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer

Azacitidine in Lower‐Risk Myelodysplastic Syndromes: A Meta‐Analysis of Data from Prospective Studies

P121 Patients with hematologic disorders receiving azacitidine who are enrolled in AVIDA, a longitudinal patient registry, achieve transfusion independence

Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation

Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?

Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation

A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer

High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer : a 10-year experience

Autologous and allogeneic transplantation for aggressive NHL

A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma

Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer

Toward understanding toxicity over time (ToxT) in myeloma cooperative group trials: Feasibility of a novel longitudinal adverse event analysis in ECOG-ACRIN E1A06

Patients with secondary myelodysplastic syndromes (MDS) who are enrolled in AVIDA, a longitudinal registry for patients receiving azacitidine (AZA)

Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma

Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer

Factors Affecting the Results of Allogeneic Hematopoietic Stem Cell Transplantation in Hematologic Malignancies

Response of pancreatic carcinoma to 5-fluorouracil and leucovorin

Outcome of Submyeloablative Allogeneic HSCT for Hematologic Malignancies: Development of a Prognostic Model Based on Pre-Transplant Characteristics

Ideal (IBW) Rather Than Actual (ABW) Body Weight Should Be Used To Calculate Cell Dose in Allogeneic HSCT

Identifying Patients at Risk of Early Relapse after Submyeloablative Allogeneic HSCT

Graft CD3+ Cell Content Affects Acute GVHD after Submyeloablative Allogeneic HSCT

The Effect of the Platelet Content of Blood Stem Cell Grafts on GVHD

Is a Younger 10-Allele-Matched Unrelated Donor (MUD) Better Than an Older 6-Antigen-Matched Sibling Donor (MSD) for Allogeneic HSCT?

Suchergebnisse filtern